– USA, WA – Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Dr Ted W. Love, M.D. to its Board of Directors.
Dr. Love has more than 25 years of global experience in the healthcare and biotechnology/pharmaceutical industry and currently serves as President and CEO of Global Blood Therapeutics.
“We are pleased to welcome Ted to our Board of Directors given his distinguished industry expertise and leadership,” said CEO, Dr Clay Siegall. “His extensive experience will be a valued addition at this transformational time for our company, with three marketed products, significant development across our pipeline and an expanding global footprint. We look forward to working with Ted on our quest to improve the lives of people with cancer through innovative medicines that address unmet medical needs.”
Concurrent with the appointment of Dr. Love, Dr Srinivas Akkaraju, M.D.,PhD, has resigned from the Board of Directors where he has served since 2003.
“I want to thank Srini for his incredible contributions over more than 17 years,” added Dr. Siegall. “He has played an instrumental role in building Seattle Genetics to the global, multi-product company that it is today.”
About Dr Ted Love
Prior to Dr. Love’s current role at Global Blood Therapeutics, he held executive positions at a number of biopharmaceutical companies including Onyx Pharmaceuticals, Nuvelo, Inc. and Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions at Genentech, where he oversaw the development strategy and execution that led to the approvals of six innovative medicines. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Royalty Pharma and the Biotechnology Innovation Organization and has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. ADCETRIS and PADCEV use the Company’s industry-leading antibody-drug conjugate technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA, a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union.
For more information: https://www.seattlegenetics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
